Canopy Growth (CGC)

Canopy Growth Stock Analysis & Ratings



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Canopy Growth’s price range in the past 12 months?
Canopy Growth lowest stock price was $2.13 and its highest was $19.85 in the past 12 months.
    What is Canopy Growth’s market cap?
    Currently, no data Available
    What is Canopy Growth’s price target?
    The average price target for Canopy Growth is $4.08. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $10.05 ,the lowest forecast is $1.93. The average price target represents 30.35% Increase from the current price of $3.13.
      What do analysts say about Canopy Growth?
      Canopy Growth’s analyst rating consensus is a ‘Moderate Sell. This is based on the ratings of 13 Wall Streets Analysts.
        When is Canopy Growth’s upcoming earnings report date?
        Canopy Growth’s upcoming earnings report date is Nov 09, 2022 which is in 93 days.
          How were Canopy Growth’s earnings last quarter?
          Canopy Growth released its earnings results on Aug 05, 2022. The company reported -$4.044 earnings per share for the quarter, missing the consensus estimate of -$0.221 by -$3.823.
            Is Canopy Growth overvalued?
            According to Wall Street analysts Canopy Growth’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Canopy Growth pay dividends?
              Canopy Growth does not currently pay dividends.
              What is Canopy Growth’s EPS estimate?
              Canopy Growth’s EPS estimate is -$0.21.
                How many shares outstanding does Canopy Growth have?
                Canopy Growth has 479,978,730 shares outstanding.
                  What happened to Canopy Growth’s price movement after its last earnings report?
                  Canopy Growth reported an EPS of -$4.044 in its last earnings report, missing expectations of -$0.221. Following the earnings report the stock price went down -6.574%.
                    Which hedge fund is a major shareholder of Canopy Growth?
                    Among the largest hedge funds holding Canopy Growth’s share is GMT Capital Corp. It holds Canopy Growth’s shares valued at 2M.


                      Canopy Growth Stock Analysis

                      The Canopy Growth stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Canopy Growth

                      Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

                      Similar Stocks
                      Price & Change
                      TerrAscend Corp

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis